NCT06907524 Preventative Screening and Health Coaching in a Food Insecure Population
| NCT ID | NCT06907524 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rush University Medical Center |
| Condition | Cardiovascular Disease Prevention |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-03-01 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population. The main questions it aims to answer are: * Does longitudinal, individualized health coaching directed at lifestyle modification reduce patient 10-year risk of heart attack or stroke? * Does longitudinal, individualized health coaching directed at lifestyle modification reduce rates of hypertension, hyperlipidemia, and diabetes? * Does longitudinal, individualized health coaching directed at lifestyle modification improve accessibility to healthcare? Researchers will investigate the effects of regularly scheduled health coaching sessions on composite cardiometabolic risk profile as well as individual modifiable cardiovascular risk factors. Participants will: * Participate in in-person cardiovascular screening, occuring at the time of enrollment, months 3 and 6. * Engage in virtual health coaching sessions to talk about diet, exercise, weight loss, blood pressure and diabetes control, and accessibility to healthcare * Keep a log of their blood pressure
Eligibility Criteria
Inclusion: * Patient is a participant at a CHI sponsored, community screening event * Patient provides informed consent and willingness to participate for the duration of the study * English or Spanish speaking * Age 40-75 years old * At least 1 cardiometabolic risk factor at suboptimal level, defined as one or more of the following at initial screening: * Systolic BP greater than 130mmHg and/or diastolic BP greater than 80mmHg. * Body mass index (BMI) greater than 30 〖kg/m〗\^2 * Total cholesterol greater than 200 mg/dL * Triglycerides greater than 150 mg/dL * Low density lipoprotein (LDL) greater than 130 mg/dL * High density lipoprotein (HDL) less than 40 mg/dL in men or less than 50 mg/dL in women * Hemoglobin A1c greater than or equal to 5.7% * 10-year ASCVD score greater than 5% * Access to a telehealth compatible device Exclusion: * Adults unable to provide informed consent or unwilling to participate for study duration * Speaks language other than English or Spanish * Younger than 40 years old or older than 75 years old * All cardiometabolic risk factors at optimal levels * No telehealth compatible device * Pregnant patients
Contact & Investigator
Daniel Luger, MD
PRINCIPAL INVESTIGATOR
Rush University Medical Center
Frequently Asked Questions
Who can join the NCT06907524 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 75 Years, studying Cardiovascular Disease Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06907524 currently recruiting?
Yes, NCT06907524 is actively recruiting participants. Contact the research team at daniel_luger@rush.edu for enrollment information.
Where is the NCT06907524 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06907524 clinical trial?
NCT06907524 is sponsored by Rush University Medical Center. The principal investigator is Daniel Luger, MD at Rush University Medical Center. The trial plans to enroll 200 participants.